Gujarat Themis Biosyn Ltd · NSE:GUJTHEM
Gujarat Themis Biosyn — Q3 FY2023-24 Earnings Presentation
15 slides from Gujarat Themis Biosyn's earnings presentation, Feb 10, 2024
Slide 1: Cover letter: Investor Presentation submission to BSE
GUJARAT THEMIS BIOSYN LIMITED CIN: L24230GJ1981PLC004878 REGD. OFFICE &FACTORY : 69/C GIDC INDUSTRIAL ESTATE, VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA TEL : 0260-2430027 / 2400639 E-mail:hrm@gtbl.in.net GTBL: CS: BSE-CORR/2023-24 10th February, 2024 The Manager, Corporate Relationship Department
Slide 2: Result Update Presentation Q3 & 9M FY23-24
Gujarat Themis Biosyn Limited Result Update Presentation Q3 & 9M FY23-24
Slide 3: Disclaimer
Click to edit Master title style Disclaimer This presentation has been prepared by Gujarat Themis Biosyn Limited (the “Company” or “GTBL”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form t
Slide 4: Management Comment
Click to edit MasterComment Management title style Commenting on the result, Dr. Sachin Patel, Director said: “The Company has performed in line with expectations during the third quarter of this fiscal year. We continued to operate at near full capacity as the slowness in tendering has eased out, o
Slide 5: Quarterly Financial Highlights
Click to edit Master Quarterly titleHighlights Financial style Revenue (Rs. Cr) 49.6 39.7 38.9 28.2 28.2 Q3 FY22-23 Q4 FY22-23 Q1 FY23-24 Q2 FY23-24 Q3 FY23-24 EBITDA (Rs. Cr) / Margin (%) PAT (Rs. Cr) / Margin (%) 25 53.0% 47.4% 60% 20 41.5% 45% 45.7% 50% 20 43.0% 42.4% 18 35.7% 34.8% 33.5% 40% 40%
Slide 6: Q3 FY23-24 Financial Highlights
Click to Q3edit Master FY23-24 title style Financial Highlights Rs. Crs Q3 FY23-24 Q3 FY22-23 YoY% Q2 FY23-24 Income from Operations 38.86 28.17 39.65 Other Operating Income 0.00 0.00 0.00 Total Income from Operations 38.86 28.17 37.97% 39.65 Cost of Materials Consumed 6.35 7.44 6.76 Changes In Inve
Slide 7: 9M FY23-24 Financial Highlights
Click to 9Medit Master FY23-24 title style Financial Highlights Rs. Crs 9M FY23-24 9M FY22-23 YoY% Income from Operations 128.10 120.80 Other Operating Income 0.00 0.00 Total Income from Operations 128.10 120.80 6.04% Cost of Materials Consumed 19.53 22.77 Changes In Inventory 8.90 1.74 Employee Cos
Slide 8: Annual Financial Highlights
Click to edit Master Annual Financialtitle style Highlights Revenue (Rs. Cr) 148.97 114.85 85.12 90.56 41.05 FY18-19 FY19-20 FY2021 FY21-22 FY22-23 EBITDA (Rs. Cr) / Margin (%) PAT (Rs. Cr) / Margin (%) 80 49.8% 60% 50.5% 70 70 38.9% 45% 44.5% 50% 38.0% 60 37.4% 60 33.3% 40% 27.8% 35% 40% 50 58.0 50
Slide 9: Balance Sheet Highlights
Click to edit Master Balance title style– As on 30th September 2023 Sheet Highlights Rs. Cr. Rs. Cr. Sept 2023 Mar 2023 Sept 2023 Mar 2023 Total Equity & Liabilities Total Assets Shareholders Funds 177.99 149.15 Non Current Assets 149.32 105.48 Share Capital 7.26 7.26 Property Plant & Equipment 34.6
Slide 10: Key Balance Sheet Ratios
Click to Keyedit Master Balance title Sheet style Ratios RoCE(%)* RoA(%)** 37.0% 35.6% 34.9% 70.91% 34.2% 59.9% 57.9% 52.1% 19.6% 33.94% FY18-19 FY19-20 FY20-21 FY21-22 FY22-23 FY18-19 FY19-20 FY20-21 FY21-22 FY22-23 RoE(%)*** 56.1% 43.2% 42.2% 38.9% 34.6% FY18-19 FY19-20 FY20-21 FY21-22 FY22-23 ***
Slide 11: Among India's few fermentation based Intermediate manufacturers
Click Among to edit India’s Masterfew title style Fermentation based Intermediate manufacturer GTBL among one of India’s few fermentation-based manufacturers in pharmaceutical field State of Art Manufacturing Facility Incorporated in 1981 as joint Plant in Vapi (Gujarat) sector Company with GIIC
Slide 12: Product Portfolio – Growing at a fast pace
Click toStrong edit Master & Niche title style Product Portfolio – Growing at a fast pace Current Product Portfolio Rifamycin An intermediate for Rifamycin S An intermediate for manufacturing drug Rifampicin O manufacturing drug Rifaximin (Anti biotic used for treatment of (Antibiotic used for t
Slide 13: State of Art Manufacturing Facilities at Vapi
Click to editofMaster State title style Facilities at Vapi Art Manufacturing Among very few companies in India with fermentation capabilities for Intermediates Environment Friendly & Sustainable Process Using Aerobic Bacteria for Fermentation 12
Slide 14: Our Way Ahead
Click to Ouredit Way Master Aheadtitle style In process of identifying new products which have good domestic and export New Product Development & potential Company working on strategy to move up the value chain by way of forward Forward Integration integration into API New infrastructure being
Slide 15: Thank You
Click to editYou Thank Master title style For further information, please contact: Company : Investor Relations Advisors : Gujarat Themis Biosyn Limited Adfactors PR Pvt. Ltd. Mr. Sangameshwar Iyer Ms. Savli Mangle - 9833361003 Mr. Rahul Trivedi - 9833541841 sangameshwar.iyer@themismedicare.com savl
Gujarat Themis Biosyn — Q3 FY2023-24 Earnings Presentation on 6ix